Results 171 to 180 of about 4,805 (202)
Some of the next articles are maybe not open access.
Selinexor dose optimization: A retrospective analysis.
JCO Oncology Practice296 Background: Several oral oncolytics are approved at doses that require early and frequent intervention to manage associated toxicities. This retrospective analysis investigated efficacy and safety outcomes of patients initiated on lower doses (≤ 80 mg) of selinexor compared to those who ...
Rachel Hauf +8 more
openaire +1 more source
LncRNA HCG11 regulates selinexor sensitivity in multiple myeloma
Biochemical PharmacologyMultiple myeloma (MM) is an incurable plasma cell caner featured by monoclonal plasma cell proliferation in bone marrow. The patients inevitably encounter drug resistance and the cancer relapse. Selinexor, a selective inhibitor of nuclear export by targeting exportin-1 (XPO1), is a novel medication in MM treatment.
Yue Zhang +18 more
openaire +2 more sources